Krazati fails confirmatory trial in colorectal cancer, putting approval at risk
Bristol Myers Squibb’s cancer drug Krazati has failed its confirmatory study in second-line colorectal cancer, a company spokesperson confirmed to Endpoints News. Krazati had received accelerated approval in 2024 in this setting. But a Phase ...
ORIGINAL SOURCE →via Endpoint News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · conflict
- [CONFLICT] Intermodal Asia
- [CONFLICT] İran duyurdu: Hazırlıklar tamam! Babülmendep Boğazı kapanıyor
- [CONFLICT] Dev medya grubunun CEO’sundan çalışanlara tehdit: Ya İsrail'i destekleyin ya da istifa edin
- [CONFLICT] Fenerbahçe Beko, Zalgris serisinde kazanmaya devam ediyor
- [CONFLICT] Elections Committee head Orly Ades steps down after 16 years, half a year before Knesset elections
- [CONFLICT] İlk kez 1936 Berlin Olimpiyatlarında güreşte madalya kazanan Türkiye, güreş dışındaki ilk madalyasını 1948 Londra Olimpiyatlarında hangisinde kazanmıştır?